An interventional study of Intestinal microbiota suspension in Delirium, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Delirium with a site in China — 29 open to participants now, 30 under way, none of them phase 3. Delirium · China.
Among the 96 studies in Delirium with a site in China, this one is the 59th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2026, is one of 40 with no phase, reaches primary completion later than 27 of the 29 other live ones, and was the 90th registered.
935 studies on the registry are indexed under Delirium; 188 are open to participants now.
Browse Delirium studies →29 of the 96 studies in Delirium with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Chinese University of Hong Kong · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–80
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 111 across 551 interventional studies indexed under Delirium.
Median enrollment 262 across the 66 interventional studies, 249 across the 30 observational. Of the 42 that completed or were terminated, 5 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 96 have an industry lead sponsor. The 10 most frequent:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 183 studies on the registry; 146 are open to participants now.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology has 1 study filed under Delirium — fewer than ten, so there is no comparison to draw.
8 of the studies in Delirium with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06007755Huazhong University of Science and TechnologyExploring of Serum Biomarkers of Delirium After Cardiovascular Surgery | 2026-12 |
| NCT04832568Huazhong University of Science and TechnologyPerioperative EEG-Monitoring and Postoperative Delirium in Patients Undergoing Cardiovascular Surgery | 2026-12 |
| NCT04091724Huazhong University of Science and TechnologyPerioperative EEG-Monitoring and Emergence Delirium in Children | 2026-12 |
| NCT04789733The Cleveland ClinicThe GUARDIAN Pilot Trial | 2026-12-31 |
| NCT05525702Peking Union Medical College HospitalVR Interventions to Reduce the Prevalence of Delirium in ICU Patients | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 96 studies in Delirium with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Delirium in the intensive care unit (ICU) is a prevalent and serious neurological complication among critically ill patients, with large multicenter studies reporting an incidence of 30% to 80%, particularly in those requiring mechanical ventilation. Delirium is not only associated with prolonged ICU and hospital stays but also with increased morbidity and mortality. Notably, up to 40% of survivors suffer from persistent cognitive dysfunction that may last for months or even years. Despite current standard pharmacological interventions-such as haloperidol and second-generation antipsychotics-failing to demonstrate significant clinical benefit in phase III trials, non-pharmacological strategies remain challenging to implement due to environmental and operational constraints within the ICU. This unmet clinical need underscores the imperative to develop novel, effective therapeutic approaches.
Emerging evidence suggests that ICU-acquired gut microbiota dysbiosis plays a pivotal role in the pathogenesis of delirium. Dysbiosis can compromise intestinal barrier integrity, promoting systemic inflammation and increasing susceptibility to various forms of delirium, including acute illness-related and postoperative types. These effects are likely mediated through the "gut-microbiota-brain axis," which may represent a central mechanism underlying neurocognitive dysfunction in critical illness.
Preclinical studies have demonstrated that fecal microbiota transplantation (FMT) can restore microbial balance and exert beneficial effects on neurological function. FMT has shown promise in ameliorating cognitive deficits in models of Alzheimer's disease, chronic cerebral hypoperfusion, traumatic brain injury, and chronic unpredictable mild stress (CUMS). Clinically, FMT has been associated with cognitive improvement in patients with dementia, recurrent Clostridioides difficile infection, and sepsis-associated encephalopathy. With expanding applications in both gastrointestinal and extraintestinal disorders, FMT has emerged as a transformative therapeutic modality, supported by robust short- and long-term safety and efficacy data.
This study aims to evaluate whether FMT can alleviate delirium severity, correct gut microbiota dysbiosis at 0, 72, and 120 hours post-enrollment, attenuate intestinal barrier dysfunction, reduce systemic inflammation and disease severity, shorten ICU length of stay, and lower rates of ICU mortality, in-hospital mortality, and 28-day all-cause mortality-ultimately positioning FMT as a potential breakthrough intervention for ICU delirium.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Routine administration of antipsychotic medications: Conventional antipsychotic therapy refers to the daily ingestion or application of any sustained-release formulation (in any dosage form) of antipsychotic drugs with the ATC code N05A (in any form), including the following agents:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The control group received standard ICU care, which includes monitoring vital signs, managing underlying conditions, infection treatment, nutritional support, and sedation or analgesia as per established clinical guidelines. These patients did not receive fecal microbiota transplantation (FMT). Treatment decisions were made by the attending physician according to standard ICU protocols and routine clinical practice.
FMT was administered via nasojejunal tube in addition to standard ICU care. A volume of 50-100 mL of intestinal microbiota suspension was delivered daily through the nasojejunal tube over a three-day period, between 11:00 and 13:00 each day.
Other: Intestinal microbiota suspension
FMT was administered via a nasojejunal tube daily for three consecutive days, between 11:00 and 13:00. Each 50-100 mL dose, derived from 100-150 g of adolescent donor feces diluted to 300 mL. Patients fasted for 2 hours before and after FMT, except for permitted water intake. Intravenous antibiotics were withheld unless active infection was confirmed. If pathogens were considered colonizing and the patient remained stable, systemic antibiotics were avoided. Localized treatments, such as nebulized antibiotics, were allowed as needed. All antibiotic use required clinical justification and individual assessment to minimize interference with FMT. Oral antibiotics were prohibited after FMT initiation to protect engraftment and microbial integrity.
Delirium-free days (DFDs)
The CAM-ICU is a standardized tool specifically designed for the rapid screening of delirium in ICU patients. It achieves efficient diagnosis by evaluating indicators including consciousness state, attention, and disordered thinking. and perceptual abnormalities. Delirium can be diagnosed if features 1 and 2 are met, and at least 3 or 4 are present. The assessment process is standardized, and medical staff can operate independently after training. For patients who survived and were discharged from the ICU or hospital during the study observation period, the entire period subsequent to their discharge date shall be counted as delirium-free. For patients who died during the study observation period, the interval from their date of death to the end of the observation period shall be recorded as 0 delirium-free days. DFDs = Total observation days - Days with delirium - Days with coma - Days from death to the end of observation.
Time frame: During the first 28 days post-enrollment
CAM-ICU-7 score
A 7-point rating scale (0-7) was derived from the CAM-ICU and RASS assessments. The final CAM-ICU-7 score ranges from 0-7 with 7 being most severe. CAM-ICU-7 scores were further categorized as 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.
Time frame: From ICU admission to ICU discharge or death during ICU stay.
Changes in intestinal microbiota composition
Metagenomic profiling of fecal samples obtained via rectal swabs to assess: Changes in alpha-diversity (Shannon index), beta-diversity (Bray-Curtis dissimilarity), and relative abundance of specific bacterial taxa.
Time frame: At 0, 72, and 120 hours post-inclusion
Alterations in serum metabolites
Serum samples were collected for non-targeted metabolomics analysis to comprehensively examine the composition and changes of endogenous small molecule metabolites in the blood.
Time frame: At 0, 72, and 120 hours post-inclusion
Acute Gastrointestinal Injury (AGI) Score
The AGI scoring system is a standardized tool in critical care for assessing gastrointestinal dysfunction severity. It divides injury into four grades based on clinical and physiological findings: Grade I involves partial gastrointestinal impairment, such as feeding intolerance or transient diarrhea; Grade II includes gastrointestinal dysfunction, like gastroparesis with aspiration risk or abdominal compartment syndrome; Grade III indicates gastrointestinal failure, marked by persistent feeding intolerance or intestinal ischemia; Grade IV features gastrointestinal failure with severe systemic consequences, including intestinal necrosis or septic shock. This system supports dynamic assessment and guides clinical intervention in critically ill patients.
Time frame: At 0, 24, 48, 72, 96, and 120 hours post-inclusion
APACHE ⅡScore
The APACHE II scoring system includes three components: the Acute Physiology Score (APS), Age Score, and Chronic Health Evaluation. The total score, ranging from 0 to 71, reflects disease severity, with higher values indicating worse condition. The APS incorporates 12 physiological variables. A built-in formula calculates individual risk of death (R); averaging all R values gives the predicted mortality rate for a patient group. APACHE II is a key tool for assessing critically ill patients in ICU.
Time frame: At 0, 24, 48, 72, 96, and 120 hours post-inclusion
Length of stay in the ICU
Duration of ICU stay, defined as the number of days from patient admission to the intensive care unit until either discharge from the ICU or in-ICU mortality.
Time frame: Up to 4 weeks after inclusion
ICU mortality rate
The ICU mortality rate is defined as the proportion of patients admitted to the ICU who die during their ICU stay, calculated as the number of deaths occurring within the ICU divided by the total number of ICU admissions, excluding patients transferred to other facilities or discharged against medical advice.
Time frame: Up to 4 weeks after inclusion
In-hospital mortality rate
The in-hospital mortality rate is a standardized clinical outcome measure defined as the proportion of patients admitted to the hospital who die during their stay, calculated as the number of deaths occurring from admission to death.
Time frame: Up to 4 weeks after inclusion
Number of days alive and discharged within 28 days
"Number of days alive and discharged within 28 days" is defined as the total number of days that a patient remains both alive and in a discharged state within the 28-day period starting from the date of the first FMT administration.
Time frame: Up to 28 days after inclusion
Number of days survived without mechanical ventilation within 28 days
"Number of days survived without mechanical ventilation within 28 days" is defined as the total number of days during the 28-day period following the first administration of FMT on which the patient remains both alive and not requiring invasive or non-invasive mechanical ventilation.
Time frame: Up to 28 days after inclusion
28-day all-cause mortality rate
The 28-day all-cause mortality rate refers to the proportion of individuals who die from any cause within 28 days following a specific event or admission, and is commonly used as a standardized outcome measure in clinical studies.
Time frame: Up to 28 days after inclusion
Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.
Of 219 non-industry interventional studies with no phase under Delirium, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 33 months is above that.
Counting every sponsor, half of 222 studies reached it within 26 months; a quarter within 12 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology →